Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 1.8% Higher – Still a Buy?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were up 1.8% during mid-day trading on Wednesday . The company traded as high as $0.24 and last traded at $0.23. Approximately 22,176,383 shares changed hands during trading, a decline of 65% from the average daily volume of 62,975,301 shares. The stock had previously closed at $0.23.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Friday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average price is $0.26 and its 200 day moving average price is $0.31. The firm has a market cap of $44.01 million, a price-to-earnings ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.